TG Therapeutics Inc [TGTX] Is Currently 0.43 below its 200 Period Moving Avg: What Does This Mean?

TG Therapeutics Inc [NASDAQ: TGTX] surged by $0.07 during the normal trading session on while it closed the day at $16.24. The company report on January 10, 2024 at 7:00 AM that TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones.

Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Preliminary year-end 2023 cash position of approximately $215 million.

TG Therapeutics Inc stock has also gained 3.64% of its value over the past 7 days. However, TGTX stock has inclined by 119.76% in the 3 months of the year. Over the past six months meanwhile, it has gained 54.81% and lost -4.92% year-on date.

The market cap for TGTX stock reached $2.46 billion, with 146.39 million shares outstanding and 136.40 million shares in the current float. Compared to the average trading volume of 6.45M shares, TGTX reached a trading volume of 5500216 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about TG Therapeutics Inc [TGTX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TGTX shares is $28.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TGTX stock is a recommendation set at 1.56. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Goldman have made an estimate for TG Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 02, 2023.

The Average True Range (ATR) for TG Therapeutics Inc is set at 1.06, with the Price to Sales ratio for TGTX stock in the period of the last 12 months amounting to 12.96. The Price to Book ratio for the last quarter was 14.93, with the Price to Cash per share for the same quarter was set at 1.51.

TGTX stock trade performance evaluation

TG Therapeutics Inc [TGTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.64. With this latest performance, TGTX shares dropped by -4.92% in over the last four-week period, additionally plugging by 54.81% over the last 6 months – not to mention a rise of 12.00% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TGTX stock in for the last two-week period is set at 49.84, with the RSI for the last a single of trading hit 49.13, and the three-weeks RSI is set at 51.69 for TG Therapeutics Inc [TGTX]. The present Moving Average for the last 50 days of trading for this stock 15.98, while it was recorded at 16.09 for the last single week of trading, and 17.00 for the last 200 days.

TG Therapeutics Inc [TGTX]: An insightful look at the core fundamentals

TG Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.95 and a Current Ratio set at 5.53.

Earnings per share (EPS) analysis for TG Therapeutics Inc [TGTX] stock

With the latest financial reports released by the company, TG Therapeutics Inc posted -0.39/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TGTX.

TG Therapeutics Inc [TGTX]: Institutional Ownership

The top three institutional holders of TGTX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in TGTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in TGTX stock with ownership which is approximately 5.8325%.